HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinical safety rating
safeNo significant drug interactions Can cause hypernatremia and fluid overload.
Heparin binds to antithrombin III, inducing a conformational change that accelerates the inactivation of thrombin (factor IIa) and activated factor X (Xa), thereby inhibiting coagulation.
| Metabolism | Primarily cleared by the reticuloendothelial system and partially metabolized in the liver (desulfation and depolymerization). Dose-dependent renal elimination of smaller molecular weight fragments. |
| Excretion | Renal (clearance primarily via reticuloendothelial system and liver, with minimal renal excretion of intact heparin; metabolites eliminated renally; <5% excreted unchanged in urine) |
| Half-life | 1.5 hours (dose-dependent and increases with higher doses; e.g., 2.5 hours after 25,000 units IV; prolonged in hepatic or renal impairment) |
| Protein binding | 95-98% (binds to antithrombin III, albumin, lipoproteins, fibrinogen, and factor V) |
| Volume of Distribution | 0.06-0.1 L/kg (primarily confined to intravascular space; minimal extravascular distribution) |
| Bioavailability | Subcutaneous: 20-30% (due to limited absorption and first-pass hepatic metabolism); IV: 100% |
| Onset of Action | IV: immediate; subcutaneous: 20-30 minutes |
| Duration of Action | IV: 2-6 hours (dose-dependent; may be prolonged with high doses or hepatic/renal impairment); subcutaneous: 8-12 hours (may extend with high doses) |
| Molecular Weight | 12000-15000 Da (average 15000 Da) |
IV infusion: Initial bolus 80 units/kg, then continuous infusion at 18 units/kg/hr. Adjust based on aPTT. Subcutaneous: 5,000-10,000 units every 8-12 hours.
| Dosage form | INJECTABLE |
| Renal impairment | No specific dose adjustment for heparin based on GFR. However, caution in severe renal impairment (CrCl <30 mL/min) due to increased bleeding risk. Use with careful monitoring. |
| Liver impairment | Heparin is primarily metabolized in the liver. In Child-Pugh class B or C, dose may need reduction due to prolonged half-life. No specific dose recommendations; monitor aPTT closely. |
| Pediatric use | IV infusion: Initial bolus 75-100 units/kg over 10 minutes, then maintenance 20-25 units/kg/hr for infants <1 year; 18-20 units/kg/hr for children >1 year. Adjust based on aPTT. |
| Geriatric use | Elderly patients may have reduced renal function and increased bleeding risk. Lower initial infusion rates (15-18 units/kg/hr) and more frequent aPTT monitoring recommended. |
| 1st trimester | Heparin does not cross the placenta; considered safe in pregnancy. No known teratogenic effects. |
| 2nd trimester | Safe for use; monitor for bleeding and heparin-induced thrombocytopenia. |
| 3rd trimester | Safe; increased risk of bleeding during delivery; consider discontinuation or reversal if needed. |
Clinical note
No significant drug interactions Can cause hypernatremia and fluid overload.
| FDA category | Animal |
| Placental transfer | No significant placental transfer due to high molecular weight and negative charge. |
| Breastfeeding | Heparin is not excreted into breast milk due to high molecular weight and negative charge; considered compatible with breastfeeding. |
| Lactation Rating | L1 (Compatible) |
| Teratogenic Risk | Heparin does not cross the placenta and is not associated with fetal teratogenicity. No increased risk of congenital anomalies reported. First trimester: no evidence of teratogenic effects. Second and third trimesters: no fetal risk; may be used for maternal conditions (e.g., VTE treatment). |
| Fetal Monitoring | Monitor maternal platelet count for heparin-induced thrombocytopenia; activated partial thromboplastin time (aPTT) for anticoagulation; signs of bleeding. Fetal monitoring: ultrasound for growth if used long-term; no direct fetal monitoring required. |
| Fertility Effects | No known impact on fertility in males or females. Does not affect ovulation, implantation, or spermatogenesis. |
■ FDA Black Box Warning
Heparin is contraindicated in patients with a history of heparin-induced thrombocytopenia (HIT) or heparin-induced thrombocytopenia with thrombosis (HITT). Monitor platelets closely; fatal hemorrhage can occur.
| Common Effects | fluid replacement |
| Serious Effects |
Active major bleedingHistory of heparin-induced thrombocytopeniaHypersensitivity to heparin or pork productsSevere thrombocytopenia (platelet count <100,000/μL)Inability to perform appropriate coagulation monitoring
| Precautions | Risk of bleeding, especially at high doses; monitor coagulation parameters (aPTT), Heparin-induced thrombocytopenia (HIT) risk; monitor platelet counts, Hyperkalemia due to suppression of aldosterone synthesis, Osteoporosis with long-term use, Hypersensitivity reactions including urticaria, angioedema, and anaphylaxis |
| Food/Dietary | No direct food interactions with heparin; however, vitamin K-rich foods (e.g., leafy greens) may affect coagulation status of the patient, but heparin acts on antithrombin III and is not vitamin K-dependent. Maintain a consistent diet if transitioning to warfarin later. |
| Clinical Pearls | Heparin 25,000 units in 0.9% NaCl is a high-concentration preparation for continuous intravenous infusion, typically used for therapeutic anticoagulation. Verify line patency and avoid concurrent use with other IV medications. Monitor aPTT closely, with dose adjustments per institutional nomogram. Protamine sulfate (1 mg per 100 units heparin) reverses effect. Use with caution in renal impairment and history of HIT. Intramuscular administration is contraindicated due to risk of hematoma. Check platelet counts regularly to screen for HIT. |
| Patient Advice | Report any signs of bleeding (unusual bruising, blood in urine/stool, black tarry stools, prolonged bleeding from cuts, nosebleeds, gums bleeding). · Avoid aspirin, NSAIDs, or blood thinners unless prescribed by your doctor. · Use a soft toothbrush and electric razor to minimize injury. · Notify all healthcare providers (including dentists) that you are on heparin. · Do not stop or adjust the infusion rate yourself. |
Loading safety data…